Moderna (NASDAQ:MRNA) Announces Quarterly Earnings Results

Moderna (NASDAQ:MRNA - Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($3.07) earnings per share for the quarter, beating analysts' consensus estimates of ($3.59) by $0.52, Briefing.com reports. The company had revenue of $167.00 million during the quarter, compared to the consensus estimate of $93.26 million. Moderna had a negative net margin of 68.84% and a negative return on equity of 10.23%. Moderna's revenue was down 91.0% on a year-over-year basis. During the same period in the prior year, the company earned $0.19 EPS.

Moderna Stock Down 0.5 %

Shares of NASDAQ:MRNA traded down $0.59 on Friday, reaching $125.00. The company had a trading volume of 4,512,362 shares, compared to its average volume of 4,144,759. The stock has a market capitalization of $47.86 billion, a P/E ratio of -10.07 and a beta of 1.57. The stock has a 50-day moving average price of $105.05 and a 200 day moving average price of $94.37. Moderna has a twelve month low of $62.55 and a twelve month high of $142.79. The company has a quick ratio of 3.36, a current ratio of 3.42 and a debt-to-equity ratio of 0.04.

Insider Activity at Moderna

In other Moderna news, CFO James M. Mock sold 647 shares of the company's stock in a transaction that occurred on Thursday, February 29th. The stock was sold at an average price of $94.57, for a total transaction of $61,186.79. Following the completion of the sale, the chief financial officer now owns 4,300 shares of the company's stock, valued at $406,651. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, Director Noubar Afeyan sold 15,000 shares of the business's stock in a transaction on Wednesday, March 13th. The shares were sold at an average price of $108.54, for a total transaction of $1,628,100.00. Following the transaction, the director now owns 2,131,931 shares of the company's stock, valued at $231,399,790.74. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO James M. Mock sold 647 shares of the stock in a transaction on Thursday, February 29th. The shares were sold at an average price of $94.57, for a total transaction of $61,186.79. Following the completion of the sale, the chief financial officer now directly owns 4,300 shares of the company's stock, valued at $406,651. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 139,954 shares of company stock valued at $14,822,576. Corporate insiders own 15.70% of the company's stock.

Analysts Set New Price Targets

Several analysts recently commented on the stock. Canaccord Genuity Group increased their target price on shares of Moderna from $91.00 to $106.00 and gave the company a "hold" rating in a research note on Friday. Jefferies Financial Group reissued a "buy" rating and set a $125.00 price objective on shares of Moderna in a research note on Tuesday, April 9th. William Blair reaffirmed a "market perform" rating on shares of Moderna in a report on Monday, April 1st. Needham & Company LLC reissued a "hold" rating on shares of Moderna in a research note on Thursday. Finally, Oppenheimer upped their price objective on shares of Moderna from $142.00 to $163.00 and gave the company an "outperform" rating in a research note on Friday. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and six have issued a buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and an average price target of $129.55.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.